Protein and Exercise to Counteract Frailty in Older Adults

May 14, 2020 updated by: Paolo Caserotti, University of Southern Denmark

Effects of High-protein Diet Combined With Exercise to Counteract Frailty in Pre-frail and Frail Community-dwelling Older Adults: a Three-arm Randomized Controlled Trial

The purpose of this study is to determine the effects of interventions with high-protein diet alone or in combination with resistance training on muscle mechanical function (muscle power and strength), frailty status, functional performance, muscle mass and quality of life.

Study Overview

Detailed Description

Study design: two-phase randomized controlled trial with three arms.

Phase 1 stabilization phase lasting one month. Participants with low protein intake (<1.0 g/kg/day) are provided with national guidelines for daily protein intake and publicly available information material and recommended to increase their protein intake to meet the guidelines. Compliance to the recommendation/ guidelines (eating >1.0 g/kg/day) will be evaluated by 4-day food records at the end of the stabilization phase. Only compliant participants are eligible for phase 2. Participants that are not compliant will be followed as "natural observational group" but will not be considered for the primary statistical analysis. Data collection in these participants will only include assessment of selected demographic, functional and nutritional parameters and semi-structured interviews to identify potential barriers for not improving protein intake. Semi-descriptive data will be presented if possible.

Phase 2: Three-arm randomized controlled trial lasting four months:

i) Protein-only (PROT): participants will receive milk-based protein-rich products with the aim of targeting a daily protein intake of 1.5 g/kg; ii) Exercise and Protein (EXEPROT): participants will receive the protein intervention as in the PROT-group combined with progressive explosive type heavy-resistance strength training two times per week iii) Recommendations (REC) participants receive the national nutritional recommendations for older adults and are recommended to follow these recommendations over the course of the study.

Nutritional data will be collected pre and post the stabilization phase. Collection of the primary and secondary outcomes will occur at baseline (pre phase 2) and at the 4-month follow-up (post phase 2). Nutritional assessment will also be evaluated halfway, at the 2-month follow-up.

Compliance Adherence to the exercise protocol and protein supplementation is recorded during the study. For the exercise protocol adherence will be considered as achieving minimum to 75% of valid training sessions, considered as minimum 70% of the exercises planned for each session. For the protein supplementation, adherence will be evaluated as daily protein intake of ≥ 1.35 g/kg (estimated from 24 hours recall and four-day food records) at the 2-month follow-up and at the 4-months follow-up. Compliance will also be estimated from during each delivery of products with a set of questions (e.g. how much of the supplement is consumed? Any changes to the habitual food intake?) and regular phone follow-ups. If participants are unable to reach the protein target additional face to face or phone interview will be planned to support adherence. For the REC-group adherence is defined as following the recommended intake of protein (1.0-1.3 g/kg/day).

Sample size and statistics Lower leg muscle power is the primary outcome of this study. Due to lack of studies similar to this study design (e.g. age and frailty status of the participants, type of exercise and level of protein supplementation) the investigators have calculated sample size using a combination of studies and methods. Based on findings from a 2017 study the effect of 12-weeks of protein supplementation (two daily supplements of 20 g milk protein) in combination with resistance training in +80-year-old healthy adults increased muscle power by 15% (SEM ± 5%) in comparison with -7% (SEM ± 6%) in the control group (receiving protein supplementation only). A result from a 2018 study indicate that 12 weeks of nutritional supplementation (0.8 g/kg/day, 1.2 g/kg/day or 1.5 g/kg/day) to pre-frail or frail older adults >70 years resulted in an increase in muscle mass (estimated by Dual energy X-ray Absorptiometry, DXA) of approximately 4% in the group receiving 1.5 g/kg/day. Unpublished data from the investigators research group show that change in muscle mass (estimated by DXA) accounted for 1,95% of the change in muscle power in older adults following 12 weeks of resistance training. Hence, the estimated effect of an increase in muscle mass of 4% on muscle power is 7,8%. Adding this to the results from the 2017 study gives an estimated change on 0,8% in the PROT-group. Assuming, that the change in muscle mass are comparable in the three groups the investigator therefore expect a change in muscle power of 15%, 0,8% and -7% with a standard deviation (SD) of 30 in the EXEPROT-, PROT- and REC-group, respectively.

Setting a power of 0.8 sample size with 37 participants in each arm should be enough to detect a significant difference in muscle power (significance level at 0.05). Adding 25% to account for dropouts a total of 150 participants is needed.

Intention-to-treat analysis will be performed. In addition, per-protocol analysis of participants that are compliant to the protocol will be performed.

Study Type

Interventional

Enrollment (Anticipated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Odense, Denmark, 5230
        • Recruiting
        • University of Southern Denmark
        • Contact:
        • Contact:
        • Principal Investigator:
          • Paolo Caserotti, PhD
        • Sub-Investigator:
          • Sussi F. Buhl, MSc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

80 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Community-dwelling adults ≥ 80 years
  • Pre-frail or frail (evaluated by the physical frailty questionnaire, SHARE-FI75+)
  • Intact cognitive function (Mini Mental State Evaluation ≥4)
  • Medically stable evaluated by medical screening including blood sample
  • Able to participate in group-based exercise without personal assistance
  • Able to understand, read and write Danish

Exclusion Criteria:

  • Allergic/ intolerant to the interventions (kidney diseases, lactose intolerance etc.)
  • On a weight losing diet

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exercise and Protein (EXEPROT)
Participants in EXEPROT receive: a high-protein diet combined with Resistance training. The high-protein diet is based on milk-based protein-rich products to supplement the habitual diet (corresponding to a protein intake of 1.5 g/kg/day). 4-day food records are used to estimate the needed protein. Of the shelf-products (e.g. milk, cheese) are used considering the individually preferences. Products are delivered once a week. The training intervention includes progressive explosive type heavy-resistance training two times per week. The intervention runs for 16 weeks. Adherence to the training protocol is monitored at each session. Adherence with the nutrition protocol is monitored daily plus at phone follow-ups where participants are asked about e.g. appetite, weight, habitual intake.
Supervised progressive explosive type heavy-resistance training two times per week
Daily supplementation with milk-based protein-rich products
Active Comparator: Protein-only (PROT)

Participants in PROT-group receive the nutritional intervention: The high-protein diet.

The diet is based on daily milk-based protein-rich products to supplement the habitual diet (corresponding to a total protein intake of 1.5 g/kg/day). The needed amount of protein supplementation is estimated from 4-day food records. Of the shelf-products (e.g. milk, skyr, cheeses) are used considering the individually preferences. Products will be delivered once a week at the home of the participant. The intervention runs for 16 weeks.

Adherence with the nutrition protocol is monitored daily (registration of compliance with the dietary plan) as well as at phone follow-ups where participants are asked about e.g. changes in appetite, weight, and habitual intake.

Daily supplementation with milk-based protein-rich products
Active Comparator: Recommendations (REC)

Participants in the REC-Group receive the comparative intervention: Recommendations.

The official national dietary recommendations for adults >65 years, developed by the Ministry of Environment and Food of Denmark, and related materials is given to the participants and they are encouraged to follow the guidelines (recommending a protein intake of 1.0-1.3 g/kg/day). The intervention runs for 16 weeks.

During the intervention all groups will receive two seminars on specific topics related to healthy ageing (e.g. talks on physical activity, sedentary behaviour, and nutrition).

Provided with the official national recommendations on nutrition

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes from baseline lower leg muscle power at 4 months
Time Frame: Baseline and 4-month follow-up
Lower leg muscle power will be assessed unilaterally using the Nottingham Leg Rig
Baseline and 4-month follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes from baseline physical frailty status at 4 months
Time Frame: Baseline and 4 months follow-up
Changes in frailty status will be evaluated by the physical frailty questionnaire (SHARE-FI75+) and the slightly modified version of the Frailty Phenotype assessment tool developed by Fried.
Baseline and 4 months follow-up
Changes from baseline countermovement jump muscle power at 4 months
Time Frame: Baseline and 4-month follow-up
Weight-bearing multi-joint motor task, countermovement jump, with a linear encoder.
Baseline and 4-month follow-up
Changes from baseline leg press and handgrip muscle strength at 4 months
Time Frame: Baseline and 4-month follow-up

Lower limb muscle strength will be measured during a maximal voluntary isometric leg press test (MVC). Subjects are seated in a custom-built unilateral leg press device (knee and ankle angles of 120 and 90, respectively) while pushing against a fixed instrumented force plate as hard and fast as possible with the dominant leg against. Muscle strength, contractile Rate of Force Development (RFD) and impulse will be determined in the trial with the highest resultant peak force.

Handgrip: Maximal isometric handgrip strength will be assessed unilaterally using a handheld dynamometer

Baseline and 4-month follow-up
Changes from baseline Short Physical Performance Battery test at 4 months
Time Frame: Baseline and 4-month follow-up
Physical function will be measured with the Short Physical Performance Battery (SPPB) which consists of three items (balance, 3 or 4 meters walking and repeated chair rise). Score ranges from 0-12 (each item has a score between 0 and 4).
Baseline and 4-month follow-up
Eating Symptom Questionnaire
Time Frame: Baseline
Evaluated by a validated eating ability questionnaire. For each symptom participant range from none to severe.
Baseline
Risk of Dysphagia
Time Frame: Baseline
Evaluated by a validated questionnaire, the EAT-10. Resulting in a score ranging from 0-40
Baseline
Appetite
Time Frame: Baseline
Evaluated by a validated questionnaire the Simplified Nutritional Appetite Questionnaire. Score range from 4-20.
Baseline
Changes from baseline anthropometry waist and hip circumference at 4 months
Time Frame: Baseline and 4 months follow-up
Waist and hip circumference (cm) will be measured using a standard ruler.
Baseline and 4 months follow-up
Changes from baseline body weight at 4 months
Time Frame: Baseline and 4 months follow-up
Body weight will be measured to using a transportable scale. Participants will be measured without shoes and wearing light clothing.
Baseline and 4 months follow-up
Changes from baseline lean and fat mass at 4 months
Time Frame: Baseline and 4 months follow-up
Changes in lean mass and fat mass will be estimated by Bioelectrical Impedance Analysis.
Baseline and 4 months follow-up
Changes from baseline lean and fat mass and bone mineral density) to 4 months
Time Frame: Baseline and 4 months follow-up
Changes in body composition (lean and fat mass and bone mineral density) will be measured by Dual-energy X-ray Absorpmetry.
Baseline and 4 months follow-up
Changes from baseline Health-related quality of life to 4 months
Time Frame: Baseline and 4-months follow-up
Health-related quality of life questionnaires (EQ-5D-3L and SF-12) will be used. Scores range from 11111-33333 and 0-100, respectively.
Baseline and 4-months follow-up
Changes from baseline pain to 4 months
Time Frame: Baseline and 4-months follow-up
Pain will be assessed by validated questionnaires (The brief pain inventory & Back and Neck pain survey questionnaire). Visual analogue scale (score 0-10) is combined with questions about intensity and frequency of pain.
Baseline and 4-months follow-up
Changes from baseline fatigue and fatigability to 4 months
Time Frame: Baseline and 4-months follow-up
Validated questionnaires will be used to assess fatigue and fatigability (Mobility Fatigue, Mob-T, & The Pittsburgh Fatigability Scale). Scores ranging from 0-6 and 0-50, respectively.
Baseline and 4-months follow-up
Changes from baseline activities of daily living to 4 months
Time Frame: Baseline and 4-months follow-up
Activities of daily living will be assessed with self-report questionnaires.
Baseline and 4-months follow-up
Changes from baseline fear of falling to 4 months
Time Frame: Baseline and 4-months follow-up
Validated questionnaire will be used to assess fear of falling (the Falls Efficacy Scale - International). Score range from 16-64.
Baseline and 4-months follow-up
Changes from baseline Blood markers to 4 months
Time Frame: Baseline and 4-months follow-up
Analysis of changes in markers of health and disease will be performed, e.g. Lipid profile, Hormonal profile, protein-markers of inflammation (e.g. High Sensitive C-Reaktivt Protein (HS-CRP), soluble urokinase plasminogen activating receptor (suPAR)), vitamins and minerals.
Baseline and 4-months follow-up
Chenages from baseline Objective measures of Physical activity, sedentary behaviour, nap and sleep to 4 months
Time Frame: Baseline and 4-months follow-up
Accelerometry methodology: level and patterns of physical activity (PA), sedentary behaviour (SB), nap and sleep (NAS) will be assessed with commercially available accelerometers (e.g. Axivity, Actigraph) placed on different anatomic locations (e.g. thigh, hip) for one week.
Baseline and 4-months follow-up
Changes from baseline Self-reported Physical activity & sedentary behaviour to 4 months
Time Frame: Baseline and 4-months follow-up
Self-report questionnaire will be used to assess physical activity and sedentary behaviour (e.g. sedentary behaviour questionnaires).
Baseline and 4-months follow-up
Changes from baseline Dietary intake to 4 month
Time Frame: Baseline and 4-months follow-up
Dietary intake is estimated by Four-day food records and food frequency questionnaires. Protein intake is calculated as average g/day and g/kg/day.
Baseline and 4-months follow-up
24 hours recall
Time Frame: pre phase 1
Dietary intake is estimated from 24 hours recall. Protein intake is calculated as average g/day and g/kg/day.
pre phase 1
Changes from baseline Walking speed to 4 months
Time Frame: Baseline and 4 months follow-up
Self-selected and maximal walking speed is measured.
Baseline and 4 months follow-up
Changes from baseline Stand and reach to 4 months
Time Frame: Baseline to 4 months follow-up
The ability to stand and reach is tested
Baseline to 4 months follow-up
Changes from baseline Walking distance to 4 months
Time Frame: Baseline and 4 months follow-up
The distance walked during 2- and 6-minutesis tested.
Baseline and 4 months follow-up
Changes from baseline Upper body ball throwing to 4 months
Time Frame: Baseline to 4 months follow-up
The ability to throw a ball, using the upper body is tested.
Baseline to 4 months follow-up
Changes from baseline Rising from laying position to 4 months
Time Frame: Baseline to 4 months follow-up
the ability to rise from laying position is tested.
Baseline to 4 months follow-up
Changes from baseline Nutritional status to 4 months
Time Frame: Baseline and 4 months follow-up
Nutrititional status is estimated by validated questionnaires: the Mini Nutritional Assessment and Eating Validation Scheme. Scores range from 0-30 and 0-3, respectively.
Baseline and 4 months follow-up
Changes in Risk of poor protein intake to 4 months
Time Frame: Baseline and 4 months
The questionnaire (protein screener) is used to estimate the probability score of having a low protein intake.
Baseline and 4 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive function
Time Frame: Baseline and 4-months follow-up
The Digit Symbol Substitution Test
Baseline and 4-months follow-up
Gender
Time Frame: Baseline
Gender (male female)
Baseline
Age
Time Frame: Baseline
Age (years)
Baseline
Education
Time Frame: Baseline
Self-report education will be assessed as number of years spent in school and maximum level of education achieved.
Baseline
Marital status
Time Frame: Baseline
Marital status will be evaluated as self-report.
Baseline
Depression
Time Frame: Baseline
depression will be evaluated with validated questionnaire at baseline (Geriatric Depression
Baseline
Incontinence
Time Frame: Baseline
Incontinence will be evaluated with the International Consultation on Incontinence Questionnaire (ICIQ) questionnaire at baseline (max score 21)
Baseline
Chronic conditions
Time Frame: Baseline
Number and type of chronic conditions will be assessed as self-report
Baseline
Use of medicine
Time Frame: Baseline
Direct count of name and dose of medicines performed under medical screening. The participant will be asked to bring the medicines.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Paolo Caserotti, PhD, University of Southern Denmark

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 13, 2019

Primary Completion (Anticipated)

June 1, 2021

Study Completion (Anticipated)

June 1, 2021

Study Registration Dates

First Submitted

February 11, 2019

First Submitted That Met QC Criteria

February 12, 2019

First Posted (Actual)

February 15, 2019

Study Record Updates

Last Update Posted (Actual)

May 18, 2020

Last Update Submitted That Met QC Criteria

May 14, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S-20180048 (Other Identifier: Regional Committee Health Research Ethics, Southern Denmark)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Physical Frailty

Clinical Trials on Resistance training

3
Subscribe